Vos, Joris L.
Zuur, Charlotte L.
Smit, Laura A.
de Boer, Jan Paul
Al-Mamgani, Abrahim
van den Brekel, Michiel W. M.
Haanen, John B. A. G.
Vogel, Wouter V. http://orcid.org/0000-0002-4992-8024
Funding for this research was provided by:
Bristol-Myers Squibb (CA209-703)
Riki Foundation
Article History
Received: 27 May 2021
Accepted: 27 October 2021
First Online: 27 December 2021
Declarations
:
: The study protocol and all its amendments were approved by the METC NKI under file number NL57794.031.16. All procedures were in agreement with the 1964 Declaration of Helsinki and consistent with Good Clinical Practice guidelines as formulated by the International Conference on Harmonization.
: All patients provided written informed consent prior to enrolment.
: All patients provided written informed consent regarding publishing their data prior to enrolment.
: Joris L. Vos, Laura A. Smit, Abrahim Al-Mamgani, and Wouter V. Vogel declare no competing interests. Charlotte L. Zuur reports receiving institutional research financial support from BMS to fund the present trial. Jan Paul de Boer reports receiving institutional research funding from Merck KGaA and institutional honoraria for an advisory role for MSD, both outside the submitted work. Michiel W.M. van den Brekel reports receiving institutional research funding from ATOS Medical, outside the submitted work. John B.A.G. Haanen reports, all outside the submitted work: institutional honoraria for advisory roles for AIMM, Amgen, BioNTech, BMS, GSK, Ipsen, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm; stock option ownership of Neogene Therapeutics; Institutional research funding from Amgen, BioNTech, BMS, MSD, Novartis.